Payment overview · 2025
General Payments
$879.95
51 reported records · 10 companies
Healthcare provider profile · identity verified
J Drew Dawson, MD
Allopathic & Osteopathic Physicians|Family Medicine · POCAHONTAS, AR · NPI 1740279553
Verified facts
What the public records show
CMS Open Payments records show J Drew Dawson, MD received $879.95 in general payments during 2025 across 51 reported records.
AstraZeneca Pharmaceuticals LP accounted for 39.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Gemtesa, Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Farxiga by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 203 claims for Eliquis by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $348.28 | 39.6% | 16 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $140.29 | 15.9% | 12 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $84.28 | 9.6% | 5 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $81.33 | 9.2% | 4 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $62.05 | 7.0% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $55.93 | 6.4% | 6 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $46.86 | 5.3% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $30.28 | 3.4% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $16.64 | 1.9% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $14.01 | 1.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $879.95 | 51 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $260.92 | 10 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $191.99 | 6 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $143.38 | 6 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $137.63 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $133.26 | 11 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $118.96 | 10 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $84.28 | 5 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $65.81 | 4 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $55.93 | 6 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $46.86 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $16.64 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $16.64 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $15.95 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $14.33 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $14.01 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $14.01 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $7.03 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 203 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 69 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 62 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
52 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
51 | 15 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
69 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
62 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
203 | 32 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 496 | 133 |
| Pantoprazole Sodium | Pantoprazole Sodium | 437 | 121 |
| Levothyroxine Sodium | Levothyroxine Sodium | 421 | 89 |
| Amlodipine Besylate | Amlodipine Besylate | 406 | 110 |
| Lisinopril | Lisinopril | 371 | 101 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 317 | 54 |
| Gabapentin | Gabapentin | 282 | 74 |
| Furosemide | Furosemide | 275 | 81 |
| Potassium Chloride | Potassium Chloride | 256 | 65 |
| Tramadol Hcl | Tramadol Hcl | 218 | 38 |
| Carvedilol | Carvedilol | 215 | 51 |
| Omeprazole | Omeprazole | 212 | 58 |
| Eliquis | Apixaban | 203 | 32 |
| Sertraline Hcl | Sertraline Hcl | 186 | 40 |
| Meloxicam | Meloxicam | 178 | 44 |
| Alprazolam | Alprazolam | 175 | 30 |
| Tizanidine Hcl | Tizanidine Hcl | 173 | 42 |
| Clopidogrel | Clopidogrel Bisulfate | 167 | 43 |
| Tamsulosin Hcl | Tamsulosin Hcl | 167 | 49 |
| Metformin Hcl | Metformin Hcl | 164 | 41 |
| Fluoxetine Hcl | Fluoxetine Hcl | 150 | 39 |
| Losartan Potassium | Losartan Potassium | 149 | 42 |
| Pravastatin Sodium | Pravastatin Sodium | 141 | 42 |
| Metoprolol Succinate | Metoprolol Succinate | 135 | 37 |
| Clonazepam | Clonazepam | 129 | 20 |
| Hydrochlorothiazide | Hydrochlorothiazide | 129 | 36 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 128 | 41 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 123 | 29 |
| Propranolol Hcl | Propranolol Hcl | 118 | 21 |
| Zolpidem Tartrate | Zolpidem Tartrate | 117 | 15 |
| Metoprolol Tartrate | Metoprolol Tartrate | 110 | 29 |
| Buspirone Hcl | Buspirone Hcl | 108 | 23 |
| Trazodone Hcl | Trazodone Hcl | 107 | 31 |
| Prednisone | Prednisone | 104 | 56 |
| Mirtazapine | Mirtazapine | 102 | 13 |
| Duloxetine Hcl | Duloxetine Hcl | 98 | 23 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 95 | 35 |
| Escitalopram Oxalate | Escitalopram Oxalate | 95 | 26 |
| Diazepam | Diazepam | 90 | 19 |
| Famotidine | Famotidine | 88 | 26 |
| Spironolactone | Spironolactone | 86 | 20 |
| Fluticasone Propionate | Fluticasone Propionate | 83 | 26 |
| Celecoxib | Celecoxib | 82 | 28 |
| Pregabalin | Pregabalin | 80 | 14 |
| Donepezil Hcl | Donepezil Hcl | 77 | 16 |
| Quetiapine Fumarate | Quetiapine Fumarate | 75 | 18 |
| Amitriptyline Hcl | Amitriptyline Hcl | 73 | 17 |
| Glimepiride | Glimepiride | 72 | 21 |
| Farxiga | Dapagliflozin Propanediol | 69 | suppressed |
| Simvastatin | Simvastatin | 68 | 21 |
| Xarelto | Rivaroxaban | 67 | suppressed |
| Bupropion Xl | Bupropion Hcl | 66 | 17 |
| Ozempic | Semaglutide | 62 | suppressed |
| Ondansetron Odt | Ondansetron | 61 | 17 |
| Lorazepam | Lorazepam | 60 | 15 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 60 | 19 |
| Anastrozole | Anastrozole | 57 | 13 |
| Metformin Hcl Er | Metformin Hcl | 57 | 17 |
| Montelukast Sodium | Montelukast Sodium | 57 | 11 |
| Sotalol | Sotalol Hcl | 54 | 13 |
| Linzess | Linaclotide | 52 | suppressed |
| Baclofen | Baclofen | 51 | 15 |
| Synthroid | Levothyroxine Sodium | 51 | 15 |
| Tresiba Flextouch U-100 | Insulin Degludec | 50 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 48 | 13 |
| Testosterone Cypionate | Testosterone Cypionate | 48 | 13 |
| Alendronate Sodium | Alendronate Sodium | 47 | 19 |
| Diltiazem Hcl | Diltiazem Hcl | 47 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 44 | suppressed |
| Lamotrigine | Lamotrigine | 43 | 11 |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 42 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 40 | 30 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 40 | 12 |
| Atenolol | Atenolol | 39 | 12 |
| Cephalexin | Cephalexin | 39 | 31 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 39 | 18 |
| Fluconazole | Fluconazole | 38 | 25 |
| Sucralfate | Sucralfate | 38 | 14 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 38 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 37 | suppressed |
| Azithromycin | Azithromycin | 37 | 34 |
| Entresto | Sacubitril/Valsartan | 37 | suppressed |
| Finasteride | Finasteride | 37 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 36 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 35 | 16 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 35 | suppressed |
| Amoxicillin | Amoxicillin | 34 | 24 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 34 | suppressed |
| Levofloxacin | Levofloxacin | 34 | 26 |
| Pioglitazone Hcl | Pioglitazone Hcl | 34 | suppressed |
| Allopurinol | Allopurinol | 33 | suppressed |
| Estradiol | Estradiol | 33 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 32 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 31 | suppressed |
| Ramipril | Ramipril | 31 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 30 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 30 | suppressed |
| Risperidone | Risperidone | 30 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 29 | suppressed |
| Jardiance | Empagliflozin | 29 | suppressed |
| Methylprednisolone | Methylprednisolone | 29 | 27 |
| Ropinirole Hcl | Ropinirole Hcl | 29 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 29 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 28 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 27 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 27 | 14 |
| Metoclopramide Hcl | Metoclopramide Hcl | 26 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 26 | suppressed |
| Pradaxa | Dabigatran Etexilate Mesylate | 26 | suppressed |
| Ezetimibe | Ezetimibe | 25 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 25 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 25 | 22 |
| Dutasteride | Dutasteride | 24 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 24 | suppressed |
| Memantine Hcl | Memantine Hcl | 24 | suppressed |
| Mounjaro | Tirzepatide | 24 | suppressed |
| Nystatin | Nystatin | 24 | 14 |
| Ondansetron Hcl | Ondansetron Hcl | 24 | 12 |
| Oxycodone Hcl | Oxycodone Hcl | 24 | suppressed |
| Repatha Sureclick | Evolocumab | 24 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 23 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 23 | suppressed |
| Lovastatin | Lovastatin | 23 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 22 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 22 | suppressed |
| Myrbetriq | Mirabegron | 21 | suppressed |
| Temazepam | Temazepam | 21 | suppressed |
| Glipizide Er | Glipizide | 20 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 19 | 18 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 19 | suppressed |
| Cilostazol | Cilostazol | 19 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 19 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 19 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 19 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 19 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Levetiracetam | Levetiracetam | 18 | suppressed |
| Methocarbamol | Methocarbamol | 18 | 13 |
| Topiramate | Topiramate | 18 | suppressed |
| Aripiprazole | Aripiprazole | 17 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 17 | 15 |
| Ventolin Hfa | Albuterol Sulfate | 17 | 11 |
| Clonidine Hcl | Clonidine Hcl | 16 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 16 | suppressed |
| Digoxin | Digoxin | 16 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 16 | 13 |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 16 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 16 | 16 |
| Primidone | Primidone | 16 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 16 | suppressed |
| Bumetanide | Bumetanide | 15 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 15 | suppressed |
| Glipizide | Glipizide | 15 | suppressed |
| Olanzapine | Olanzapine | 15 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Modafinil | Modafinil | 14 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 14 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 14 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 14 | suppressed |
| Rybelsus | Semaglutide | 14 | suppressed |
| Sod Sulf-Potass Sulf-Mag Sulf | Sodium, Potassium,mag Sulfates | 14 | 14 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | 13 |
| Tresiba Flextouch U-200 | Insulin Degludec | 14 | suppressed |
| Trulance | Plecanatide | 14 | suppressed |
| Acyclovir | Acyclovir | 13 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 13 | suppressed |
| Ibuprofen | Ibuprofen | 13 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 13 | suppressed |
| Nitroglycerin | Nitroglycerin | 13 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 13 | suppressed |
| Progesterone | Progesterone, Micronized | 13 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Eszopiclone | Eszopiclone | 12 | suppressed |
| Febuxostat | Febuxostat | 12 | suppressed |
| Latanoprost | Latanoprost | 12 | suppressed |
| Phenobarbital | Phenobarbital | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 12 | suppressed |
| Belsomra | Suvorexant | 11 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 11 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 11 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 11 | suppressed |
| Gemtesa | Vibegron | 11 | suppressed |
| Januvia | Sitagliptin Phosphate | 11 | suppressed |
| Klor-Con M20 | Potassium Chloride | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
| Novolog | Insulin Aspart | 11 | suppressed |
| Np Thyroid | Thyroid,pork | 11 | suppressed |
| Ranolazine Er | Ranolazine | 11 | suppressed |
| Trulicity | Dulaglutide | 11 | suppressed |
| Valsartan | Valsartan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $879.95 · 51 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, Cologuard Collection Kit, ELIQUIS, EVENITY, FARXIGA, GEMTESA, NURTEC ODT, OTEZLA, Ozempic, QULIPTA, REPATHA, REXULTI, Rybelsus, The Cologuard Plus Collection Kit, UBRELVY, VOQUEZNA | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error